Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Everest Medicines's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6HN vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Everest Medicines's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines (STU:6HN) has a Buyback Yield % of -17.92 as of Aug. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Everest Medicines and its competitors. According to the industry distribution chart, Everest Medicines ranks #470 out of 733 companies in the Biotechnology industry, placing it in the top 64.1%.
Is Everest Medicines' Buyback Yield % too high?
Everest Medicines' current Buyback Yield % is -17.92. Based on the distribution chart, Everest Medicines ranks #470 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Everest Medicines has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #470 out of 733 companies for Buyback Yield %. This places Everest Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Everest Medicines and its competitors. Everest Medicines's current Buyback Yield % is -17.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Everest Medicines (STU:6HN) has a current Buyback Yield % of -17.92. The stock's GF Value™ is €34.01, compared to a current price of €2.76 — trading 91.9% below its estimated fair value. The current Buyback Yield % is -17.92. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current Buyback Yield % is -17.92 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (STU:6HN) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of €2.76 is trading 91.9% below its estimated GF Value™ of €34.01.
Key valuation signals for STU:6HN:
Buyback Yield %: -17.92
GF Value™: €34.01 vs. price of €2.76 (91.9% below fair value)
No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score
Get the complete analysis for STU:6HN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6HN has been successfully added to your 
